New oral anticoagulants ‑ possible extension to other indications (Review)

Laslo,Crista Loredana; Bacalbasa,Nicolae; Stanescu,Ana Maria Alexandra; Carsote,Mara; Bungau,Simona; Rus,Marius; Bratu,Ovidiu Gabriel; Diaconu,Camelia Cristina

doi:10.3892/etm.2020.8713

New oral anticoagulants ‑ possible extension to other indications (Review)

Authors:
- Crista Loredana Laslo
- Nicolae Bacalbasa
- Ana Maria Alexandra Stanescu
- Mara Carsote
- Simona Bungau
- Marius Rus
- Ovidiu Gabriel Bratu
- Camelia Cristina Diaconu
View Affiliations

Affiliations: Internal Medicine Department, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania, ‘Carol Davila’ University of Medicine and Pharmacy, Department 13 Obstetrics‑Gynecology, ‘Ion Cantacuzino’ Clinical Hospital, 030167 Bucharest, Romania, ‘Carol Davila’ University of Medicine and Pharmacy, Family Medicine Department, 050474 Bucharest, Romania, ‘Carol Davila’ University of Medicine and Pharmacy, Department 2 Endocrinology, National Institute of Endocrinology ‘C.I. Parhon’, 011863 Bucharest, Romania, University of Oradea, Faculty of Medicine and Pharmacy, Department of Pharmacy, 410028 Oradea, Romania, University of Oradea, Faculty of Medicine and Pharmacy, Department of Medical Disciplines, 410087 Oradea, Romania, ‘Carol Davila’ University of Medicine and Pharmacy, Urology Department, Emergency University Central Military Hospital, 010825 Bucharest, Romania, ‘Carol Davila’ University of Medicine and Pharmacy, Internal Medicine Department, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania
Published online on: May 5, 2020 https://doi.org/10.3892/etm.2020.8713
Pages: 2401-2405

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anticoagulant treatment is necessary in various conditions, with curative or preventive purposes. Until recently, the only oral anticoagulants available have been vitamin K antagonists. To overcome the disadvantages of the antivitamin K oral anticoagulants, new oral anticoagulants (NOACs) have been developed and included in clinical trials. After more than 60 years of using vitamin K antagonists, the introduction of NOACs represent a medical breakthrough, with promising prospects. Due to their promising results and better safety profile, NOACs have become an appealing alternative to vitamin K antagonists in a short period of time. NOACs have been approved for the prevention and treatment of venous thromboembolism and for the prevention of stroke in patients with nonvalvular atrial fibrillation. Starting with postoperative venous thromboprophylaxis after hip replacement surgery, NOACs have been approved also for other clinical situations. Rivaroxaban is the first oral anticoagulant approved to be used in combination with an antiplatelet agent to prevent atherothrombotic events in adults with coronary artery disease and/or peripheral artery disease. However, further investigation is needed to establish which group of patients would benefit most from this medical approach. Furthermore, preliminary studies have shown that NOACs seem to be a reasonable choice of anticoagulation for patients with cancer, but further studies are expected.

View Figures

View References

1	Hull RD, Garcia DA and Vazquez SR: Warfarin and other VKAs: Dosing and adverse effects. UpToDate, Waltham, MA. 2019.https://www.uptodate.com/contents/warfarin-and-other-vkas-dosing-and-adverse-effects. Accessed May 29, 2019.
2	Mekaj YH, Mekaj AY, Duci SB and Miftari EI: New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 11:967–977. 2015.PubMed/NCBI View Article : Google Scholar
3	Abed HS, Kilborn MJ, Chen V and Sy RW: Reversal agents in the era of NOACs. J Atr Fibrillation. 10(1634)2017.PubMed/NCBI View Article : Google Scholar
4	Petca A, Petca RC, Zvanca M, Maru N, Mastalier B and Dogaroiu C: Fetal death from ruptured vasa previa: A tragic event in the ultrasonographic era. Rev Med Leg. 27:43–46. 2019. View Article : Google Scholar
5	Petca AT, Vlădăreanu S, Radu DC, BoŢ M, Berceanu C, Mastalier Manolescu BS, Medar C and Petca RC: Morphological, imaging and surgical aspects in a complex case of uterine leiomyosarcoma - case report and review of the literature. Rom J Morphol Embryol. 58:619–625. 2017.PubMed/NCBI
6	Weitz JI: Expanding use of new oral anticoagulants. F1000Prime Rep. 6(93)2014.PubMed/NCBI View Article : Google Scholar
7	European Medicines Agency: Xarelto. European Medicines Agency, 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto#authorisation-details-section. Accessed May 29, 2019.
8	European Medicines Agency: Eliquis. European Medicines Agency, 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis. Accessed May 29, 2019.
9	European Medicines Agency: Lixiana. European Medicines Agency, 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana. Accessed May 29, 2019.
10	European Medicines Agency: Pradaxa. European Medicines Agency, 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa. Accessed May 29, 2019.
11	Burke A: Pathology of Acute Myocardial Infarction. Medscape. 2015.https://emedicine.medscape.com/article/1960472-overview. Accessed October 26, 2015.
12	Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, et al: Document Reviewers: 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 34:2949–3003. 2013.PubMed/NCBI View Article : Google Scholar
13	Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, et al: ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 39:763–816. 2018.PubMed/NCBI View Article : Google Scholar
14	Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, et al: CHARISMA Investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 354:1706–1717. 2006. View Article : Google Scholar
15	Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, et al: Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 357:217–227. 2007.PubMed/NCBI View Article : Google Scholar
16	Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 41:407–477. 2020. View Article : Google Scholar
17	Stoicescu M, Csepento C, Mutiu G and Bungau S: The Role of increased plasmatic renin level in the pathogenesis of arterial hypertension in young adults. Rom J Morphol Embryol. 52 (Suppl 1):419–423. 2011.PubMed/NCBI
18	Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al: COMPASS Investigators: Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 377:1319–1330. 2017. View Article : Google Scholar
19	Brooks M: FDA Okays Rivaroxaban Plus Aspirin for Chronic CAD, PAD. Medscape. 2018.https://www.medscape.com/viewarticle/903344. Accessed October 12, 2018.
20	Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, et al: Hokusai VTE Cancer Investigators: Edoxaban for the treatment of cancer-associated venous Thromboembolism. N Engl J Med. 378:615–624. 2018.PubMed/NCBI View Article : Google Scholar
21	Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, et al: Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol. 36:2017–2023. 2018.PubMed/NCBI View Article : Google Scholar
22	McBane RD II, Wysokinski WE, Le-Rademacher J, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, et al: Apixaban and Dalteparin in Active Malignancy-Associated Venous Thromboembolism: The ADAM VTE Trial. J Thromb Haemost. 18:411–421. 2020.PubMed/NCBI View Article : Google Scholar
23	U.S. National Library of Medicine: Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer (CARAVAGGIO). uriClinicalTrials.govsimpleClinicalTrials.gov Identifier: NCT03045406. https://www.clinicaltrials.gov/ct2/show/NCT03045406. Accessed February 7, 2017.
24	Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, et al: AVERT Investigators: Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 380:711–719. 2019.PubMed/NCBI View Article : Google Scholar
25	Tica OA, Tica O, Antal L, Hatos A, Popescu MI, Stoian AP, Bratu O, Gaman MA, Pituru SM and Diaconu C: Modern oral anticoagulant treatment in patients with atrial fibrillation and heart failure: Insights from the clinical practice. Farmacia. 66:972–976. 2018. View Article : Google Scholar
26	Oprita R, Ilie M, Sandru V, Berceanu D and Constantinescu G: Gastrointestinal bleeding in patients admitted to the intensive care unit. Arch Balk Med Union. 53:544–550. 2018.PubMed/NCBI View Article : Google Scholar
27	Iliescu LE, Mercan-Stanciu A, Toma L and Ioanitescu S: Antiphospholipid syndrome - a life-threatening condition. Rev Rom Med Lab. 27:333–337. 2018. View Article : Google Scholar
28	Abdel-Daim MM, El-Tawil OS, Bungau SG and Atanasov AG: Applications of antioxidants in metabolic disorders and degenerative diseases: Mechanistic approach. Oxid Med Cell Longev. 2019(4179676)2019.PubMed/NCBI View Article : Google Scholar